Compare Campbell Soup Co. (CPB) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Campbell Soup Co. vs Enveric Biosciences Inc — how do they compare? Campbell Soup Co. trades at $19.38 (market cap $5.64B), while Enveric Biosciences Inc trades at $1.51 (market cap $6.69M). The key difference: Campbell Soup Co. is far larger — about 843× Enveric Biosciences Inc's market cap, and Campbell Soup Co. pays a 5.29% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Campbell Soup Co. for 98 Days and Enveric Biosciences Inc for 14 Days on average.
| CPB | ENVB | |
|---|---|---|
Market Cap | $5.64B | $6.69M |
Volume | 8,200,811 | 41,141 |
Sector | Consumer Staples | Health |
52-Week High | $31.66 | $10.80 |
52-Week Low | $18.90 | $1.27 |
Typical Hold Time | 98 Days | 14 Days |
Enterprise Value | $12.70B | -$1.60M |
Dividend Yield | 5.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Campbell's stock trades at $18.90, down 0.53% with bearish technical indicators. The company faces margin compression with net income margin at 4.14% and recently cut its dividend by 36% to strengthen the balance sheet. Revenue grew to $10.25B in 2025 but profitability remains under pressure. Analyst consensus shows cautious sentiment with 55% hold ratings and a $19.67 price target.
The outlook remains challenging with weak FY2027 guidance and ongoing restructuring. The $500 million cost savings program and Rao's brand growth offer potential upside, but investors face risks from declining sales, margin pressure, and competitive headwinds in the packaged foods sector.
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Campbell Soup Co.
With a history that dates back around 150 years, Campbell Soup is now a leading manufacturer and marketer of branded convenience food products, most notably soup. The firm's product assortment includes well-known brands like Campbell's, Pace, Prego, Swanson, V8, and Pepperidge Farm. Following the sale of its international snacking operations, which wrapped in calendar 2019, the firm derives nearly all of its sales from its home turf. Campbell has made a handful of acquisitions to reshape its product mix the past few years, including the tie-up with Snyder's-Lance (completed in March 2018), which enhances its exposure to the faster-growing on-trend snack food aisle, complementing its Pepperidge Farm lineup.
Read more on CPB →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
